Please Wait
Applying Filters...
menu
    • menu
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    Interquim comes from an international group of 50 companies active in the pharma, hospital, diagnostics, fine chemicals & feed sectors.

    Virtual Booth

    Contact Supplier

    Cohance Lifesciences, offers full range of CDMO services for small molecule APIs, intermediates, ADCs, Pellets and Formulations.

    Virtual Booth

    Contact Supplier

    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Menu

    Brigatinib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint
    Takeda Announces Phase 3 Trial of ALUNBRIG® (brigatinib) Met Primary Endpoint

    22 Jan 2021

    // TAKEDAONCOLOGY

    http://www.takedaoncology.com/media/news-media/news-releases/Takeda-Announces-Phase-3-Trial-of-ALUNBRIG-brigatinib-Met-Pr-10146/Print

    TAKEDAONCOLOGY
    22 Jan 2021
    Share Share
    Alunbrig scores NICE backing for ALK-positive lung cancer
    Alunbrig scores NICE backing for ALK-positive lung cancer

    11 Dec 2020

    // Lucy Parsons PHARMATIMES

    http://www.pharmatimes.com/news/alunbrig_scores_nice_backing_for_alk_lung_cancer_1359892

    Lucy Parsons PHARMATIMES
    11 Dec 2020
    Share Share
    NICE authorises Takeda's Alunbrig for ALK-positive advanced NSCLC
    NICE authorises Takeda's Alunbrig for ALK-positive advanced NSCLC

    10 Dec 2020

    // PHARMAFILE

    http://www.pharmafile.com/news/566013/nice-authorises-takedas-alunbrig-alk-positive-advanced-non-small-cell-lung-cancer

    PHARMAFILE
    10 Dec 2020
    Share Share
    ALUNBRIG?(brigatinib) now available on the NHS in England
    ALUNBRIG?(brigatinib) now available on the NHS in England

    10 Dec 2020

    // PHARMIWEB

    https://www.pharmiweb.com/press-release/2020-12-10/alunbrig-brigatinib-now-available-on-the-nhs-in-england-wales-and-northern-ireland-for-adults-with-alk-positive-advanced-non-small-cell-lung-cancer

    PHARMIWEB
    10 Dec 2020
    Share Share
    Takeda Presents New Data On Scientific Advances In Lung Cancer At ESMO
    Takeda Presents New Data On Scientific Advances In Lung Cancer At ESMO

    21 Sep 2020

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20200921005274/es

    BUSINESSWIRE
    21 Sep 2020
    Share Share
    New US approval for Takeda’s Alunbrig
    New US approval for Takeda’s Alunbrig

    25 May 2020

    // Selina McKee PHARMA TIMES

    http://www.pharmatimes.com/news/new_us_approval_for_takedas_alunbrig_1340874

    Selina McKee PHARMA TIMES
    25 May 2020
    Share Share